Author: admin

“Cystic Fibrosis Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cystic Fibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.

Some of the key takeaways from the Cystic Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years. 
• Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment 
• Emerging Cystic Fibrosis therapies in the different phases of clinical trials are- SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.   
• In September 2021, In order to assess the effectiveness and safety of VX-121 combination therapy in patients with cystic fibrosis (cf) who are heterozygous for f508del and a minimal function mutation (F/MF), Vertex Pharmaceuticals started a Phase III, randomised, double-blind, controlled research. This study’s goal is to assess VX-121/tezacaftor/deutivacaftor’s (VX-121/TEZ/D-IVA) effectiveness and safety in CF patients who are heterozygous for F508del and a minimal function mutation (F/MF patients).
• In May 2021, Vertex Pharmaceuticals Incorporated purchased the potential future milestones related to VX-561 (deutivacaftor) under the firms’ 2017 asset purchase agreement for $32 million, according to an announcement from Concert Pharmaceuticals.

Cystic Fibrosis Overview

A mutation in the epithelial chloride channel protein CFTR leads to the genetic condition known as cystic fibrosis (CF), which is a recessive condition. The severity of CF, a hereditary illness that predominates, can range from moderate to life-threatening.

Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline

Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:

• SP-101: Spirovant Sciences
• LUNAR CF: Arcturus Therapeutics
• KB407: Krystal Biotech
• VX-522: Vertex Pharmaceuticals
• Galicaftor/Navoc aftor/ABBV-576: AbbVie
• AP-PA02: Armata Pharmaceuticals
• 4D-710: 4D Molecular Therapeutics
• ELX-02: Eloxx Pharmaceutical
• Ensifentrine: Verona Pharma
• Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceuticals
• OligoG: Algi Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense

Cystic Fibrosis Route of Administration

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Cystic Fibrosis Molecule Type

Cystic Fibrosis Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Cystic Fibrosis Pipeline Therapeutics Assessment

• Cystic Fibrosis Assessment by Product Type
• Cystic Fibrosis By Stage and Product Type
• Cystic Fibrosis Assessment by Route of Administration
• Cystic Fibrosis By Stage and Route of Administration
• Cystic Fibrosis Assessment by Molecule Type
• Cystic Fibrosis by Stage and Molecule Type

DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies

Cystic Fibrosis Pipeline Analysis:

The Cystic Fibrosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
• Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies

Cystic Fibrosis Pipeline Market Drivers

• Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.

Cystic Fibrosis Pipeline Market Barriers

• However, no standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.

Scope of Cystic Fibrosis Pipeline Drug Insight    

• Coverage: Global
• Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceuticals, and others
• Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others
• Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
• Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers 

Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials

Table of Contents 

1. Cystic Fibrosis Report Introduction

2. Cystic Fibrosis Executive Summary

3. Cystic Fibrosis Overview

4. Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cystic Fibrosis Pipeline Therapeutics

6. Cystic Fibrosis Late Stage Products (Phase II/III)

7. Cystic Fibrosis Mid Stage Products (Phase II)

8. Cystic Fibrosis Early Stage Products (Phase I)

9. Cystic Fibrosis Preclinical Stage Products

10. Cystic Fibrosis Therapeutics Assessment

11. Cystic Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cystic Fibrosis Key Companies

14. Cystic Fibrosis Key Products

15. Cystic Fibrosis Unmet Needs

16 . Cystic Fibrosis Market Drivers and Barriers

17. Cystic Fibrosis Future Perspectives and Conclusion

18. Cystic Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring the Cystic Fibrosis Pipeline: FDA Approvals, Clinical Trials, Leading Therapies, and Companies Analyzed by DelveInsight | Featuring Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech

“Menkes Disease Market”

(Albany, USA) DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Menkes Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Menkes Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Request for Sample Report @ Menkes Disease Market

Menkes Disease Market Key Facts

• As per the assessment of DelveInsight, the total diagnosed prevalent cases of Menkes Disease in the G11 were found to be 265 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 6.12% during the study period.
• Among G11, the United States had 79 diagnosed prevalent cases of Menkes Disease in 2021, which was equivalent to 30% of the total diagnosed prevalent cases in G11.
• National Organization for Rare Disorders (NORD) (n.d.) has defined Menkes syndrome as an inherited X-linked recessive disorder that affects many systems in the body. The possibility of occurrence of Menkes disease is about 1 in 35,000 live male births each year. Most diagnosed infants are male; however, the disease may still occur in females, related to unusual genetic circumstances.
• According to Oprhanet (n.d.), the prevalence of Menkes syndrome at birth is estimated at 1/300,000 and 1/360,000 in Europe and Japan, respectively. The disorder is X-linked and thus primarily affects males.
• As per the study by Kaler et al. (2020) stated that assuming Harvey-Weinberg equilibrium, the allelic frequency of deleterious ATP7A variants in a genomic database from a large diverse population predicts a birth prevalence of Menkes disease or ATP7Arelated disorders as high as 1 in 8664 live male births.

Menkes Disease Overview

Menkes disease (MD), also known as Menkes syndrome, is a disorder caused by a mutation of the ATP7A gene. This ATP7A gene affects how the body transports copper and maintains copper levels. Menkes disease occurs mostly in male infants and is characterized by coarse, kinky hair (leading to its nickname of “kinky hair disease”) and failure to grow and thrive.

It is caused by pathogenic variants in ATP7A (Xq21.1) encoding a membrane-bound copper-transport protein (Cu2±transporting ATPase-alpha polypeptide). To date, about 300 different variants in this gene have been reported. There is no obvious correlation between the variants and the clinical course.

Menkes disease may not be obvious in infants until two to three months after birth when signs typically begin to appear. Low copper levels at birth do not necessarily indicate Menkes disease since many otherwise healthy infants may be born with temporarily low copper levels.

Menkes Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Menkes Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Menkes Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Menkes Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Menkes Disease Epidemiology, Segmented by –

• Total Prevalent Cases of Menkes Disease in the 7MM [2019–2032]
• Diagnosed and Treatable Cases of Menkes Disease in the 7MM [2019–2032]
• Gender-Specific Prevalent Cases of Menkes Disease in the 7MM [2019–2032]

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/menkes-disease-market

Menkes Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to be launched during the study period. The analysis covers the Menkes Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menkes Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Menkes Disease Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/menkes-disease-market

Menkes Disease Therapeutics Analysis

The Leading Companies in the Menkes Disease Therapeutics Market Include:

• Sentynl Therapeutics 
• Cyprium Therapeutics

And Many Others

Menkes Disease Drugs Covered in the Report Include:

CUTX-101 (Copper Histidinate) – Cyprium Therapeutics, in collaboration with Sentynl Therapeutics, is developing CUTX-101, a copper histidine injection to treat Menkes disease. CUTX-101 has been granted Orphan Drug designation and Rare Pediatric Disease designation by the FDA for the treatment of Menkes disease and Fast Track Designation for classic Menkes disease in patients who have not demonstrated significant clinical progression. The European Medicines Agency (EMA) Committee for Orphan Medicinal Products also granted Orphan Drug Designation for CUTX-101.

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/menkes-disease-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Menkes Disease Competitive Intelligence Analysis

4. Menkes Disease Market Overview at a Glance

5. Menkes Disease Disease Background and Overview

6. Menkes Disease Patient Journey

7. Menkes Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Menkes Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Menkes Disease Unmet Needs

10. Key Endpoints of Menkes Disease Treatment

11. Menkes Disease Marketed Products

12. Menkes Disease Emerging Drugs and Latest Therapeutic Advances

13. Menkes Disease Seven Major Market Analysis

14. Attribute Analysis

15. Menkes Disease Market Outlook (In US, EU5, and Japan)

16. Menkes Disease Access and Reimbursement Overview

17. KOL Views on the Menkes Disease Market

18. Menkes Disease Market Drivers

19. Menkes Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Menkes Disease Market is Expected to showcase Remarkable Expansion from 2023 to 2032 – DelveInsight Analysis Spotlights Sentynl Therapeutics, Cyprium Therapeutics, Others

“Traumatic Brain Injury Market”

(Albany, USA) DelveInsight’s “ Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Traumatic Brain Injury market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Traumatic Brain Injury market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Traumatic Brain Injury treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Traumatic Brain Injury market.

Request for a Free Sample Report @ Traumatic Brain Injury Market Forecast

Some facts of the Traumatic Brain Injury Market Report are:

• According to DelveInsight, Traumatic Brain Injury market size is expected to grow at a decent CAGR by 2032.
• Leading Traumatic Brain Injury companies working in the market are NeuroTrauma Sciences, SanBio, Pinteon Therapeutics, Vasopharm, NeuroVive Pharmaceutical, BioVie, Neuren Pharmaceuticals Ltd., Stemedica Cell Technologies Inc., Grace Laboratories LLC, Integra LifeSciences Corporation, Medtronic PLC, TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, and others.
• Key Traumatic Brain Injury Therapies expected to launch in the market are VAS203 (ronopterin), SB623 (vandefitemcel), Autologous HB-adMSCs, and others.
• According to Maegele et al. (2019), as determined from cases documented in the DGU Trauma Register over the period between 2013 and 2017, the incidence of hospitalization for moderate to severe traumatic brain injury (TBI) in Germany is 9.1 per 90,000 persons per year. The overall incidence is estimated at 13.6 per 90,000 persons per year.

 Traumatic Brain Injury Overview

A Traumatic Brain Injury (TBI) occurs due to sudden trauma or impact to the head, disrupting normal brain function. Its severity ranges from mild (concussions) to severe, impacting cognition, motor function, and behavior. Symptoms vary widely, including headaches, memory loss, altered consciousness, and mood swings. Immediate medical attention is crucial to prevent worsening effects. Diagnosis involves neurological exams, imaging, and cognitive assessments. Treatment focuses on stabilizing the patient, minimizing secondary injury, and rehabilitation to regain lost functions. Therapies encompass medication, cognitive therapy, physical rehabilitation, and support services. Preventive measures, like wearing helmets during activities prone to head injuries, are pivotal. TBI’s effects can be profound and require long-term care, emphasizing the need for ongoing research and support services to improve outcomes for affected individuals.

Learn more about Traumatic Brain Injury treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market

Traumatic Brain Injury Market 

The Traumatic Brain Injury market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Traumatic Brain Injury market trends by analyzing the impact of current Traumatic Brain Injury therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Traumatic Brain Injury market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Traumatic Brain Injury market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Traumatic Brain Injury market in 7MM is expected to witness a major change in the study period 2019-2032.

Traumatic Brain Injury Epidemiology

The Traumatic Brain Injury epidemiology section provides insights into the historical and current Traumatic Brain Injury patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Traumatic Brain Injury market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Traumatic Brain Injury Epidemiology @ Traumatic Brain Injury Market Dynamics

Traumatic Brain Injury Drugs Uptake

This section focuses on the uptake rate of the potential Traumatic Brain Injury drugs recently launched in the Traumatic Brain Injury market or expected to be launched in 2019-2032. The analysis covers the Traumatic Brain Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Traumatic Brain Injury Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Traumatic Brain Injury market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Traumatic Brain Injury Pipeline Development Activities

The Traumatic Brain Injury report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Traumatic Brain Injury key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Traumatic Brain Injury pipeline development activities @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market

Traumatic Brain Injury Therapeutics Assessment

Major Traumatic Brain Injury companies are working proactively in the Traumatic Brain Injury Therapeutics market to develop novel therapies which will drive the Traumatic Brain Injury treatment markets in the upcoming years are NeuroTrauma Sciences, SanBio, Pinteon Therapeutics, Vasopharm, NeuroVive Pharmaceutical, BioVie, Neuren Pharmaceuticals Ltd., Stemedica Cell Technologies Inc., Grace Laboratories LLC, Integra LifeSciences Corporation, Medtronic PLC, TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, and others.

Learn more about the emerging Traumatic Brain Injury therapies & key companies @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market

Traumatic Brain Injury Report Key Insights

1. Traumatic Brain Injury Patient Population

2. Traumatic Brain Injury Market Size and Trends

3. Key Cross Competition in the Traumatic Brain Injury Market

4. Traumatic Brain Injury Market Dynamics (Key Drivers and Barriers)

5. Traumatic Brain Injury Market Opportunities

6. Traumatic Brain Injury Therapeutic Approaches

7. Traumatic Brain Injury Pipeline Analysis

8. Traumatic Brain Injury Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Traumatic Brain Injury Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Traumatic Brain Injury Competitive Intelligence Analysis

4. Traumatic Brain Injury Market Overview at a Glance

5. Traumatic Brain Injury Disease Background and Overview

6. Traumatic Brain Injury Patient Journey

7. Traumatic Brain Injury Epidemiology and Patient Population

8. Traumatic Brain Injury Treatment Algorithm, Current Treatment, and Medical Practices

9. Traumatic Brain Injury Unmet Needs

10. Key Endpoints of Traumatic Brain Injury Treatment

11. Traumatic Brain Injury Marketed Products

12. Traumatic Brain Injury Emerging Therapies

13. Traumatic Brain Injury Seven Major Market Analysis

14. Attribute Analysis

15. Traumatic Brain Injury Market Outlook (7 major markets)

16. Traumatic Brain Injury Access and Reimbursement Overview

17. KOL Views on the Traumatic Brain Injury Market

18. Traumatic Brain Injury Market Drivers

19. Traumatic Brain Injury Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Traumatic Brain Injury Market to witness growth by 2032, estimates DelveInsight | NeuroTrauma Sciences, SanBio, Pinteon Therapeutics, Vasopharm, NeuroVive Pharmaceutical, BioVie, Neuren Pharma

“Atherosclerosis Market”

(Albany, USA) DelveInsight’s “Atherosclerosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Atherosclerosis, historical and forecasted epidemiology as well as the Atherosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atherosclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atherosclerosis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Atherosclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atherosclerosis market.

Request for a Free Sample Report @ Atherosclerosis Market Forecast

Some facts of Atherosclerosis Market Report are:

• According to DelveInsight, Atherosclerosis market size is expected to grow at a decent CAGR by 2032.
• Some of the Atherosclerosis Companies working in the market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Merck & Co, Allergan, AstraZeneca, Johnson & Johnson Private Limited, Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Gilead Sciences, Amgen Inc, Eli Lilly, AbbVie Inc, Lupin, Allergan and others.
• Increasing prevalence of cardiovascular diseases, increasing investment for healthcare infrastructure, Growing number of geriatric population, and rising incidences of high cholesterol and obesity are some factors that are believed to be driving the Atherosclerosis market.

Atherosclerosis Overview

Arteriosclerosis occurs when the blood vessels that carry oxygen and nutrients from the heart to the rest of the body (arteries) become thick and stiff — sometimes restricting blood flow to the organs and tissues. Healthy arteries are flexible and elastic. But over time, the walls in the arteries can harden, a condition commonly called hardening of the arteries.

Learn more about Atherosclerosis, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/atherosclerosis-market

Atherosclerosis Market 

The Atherosclerosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Atherosclerosis market trends by analyzing the impact of current Atherosclerosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Atherosclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Atherosclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Atherosclerosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Atherosclerosis Epidemiology 

The Atherosclerosis epidemiology section provides insights into the historical and current Atherosclerosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Atherosclerosis market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Atherosclerosis Epidemiology @ https://www.delveinsight.com/sample-request/atherosclerosis-market

Atherosclerosis Drugs Uptake

This section focuses on the uptake rate of the potential Atherosclerosis drugs recently launched in the Atherosclerosis market or expected to be launched in 2019-2032. The analysis covers the Atherosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Atherosclerosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Atherosclerosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atherosclerosis Pipeline Development Activities

The Atherosclerosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Atherosclerosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Atherosclerosis pipeline development activities @ https://www.delveinsight.com/sample-request/atherosclerosis-market

Atherosclerosis Therapeutics Assessment

Major key companies are working proactively in the Atherosclerosis Therapeutics market to develop novel therapies which will drive the Atherosclerosis treatment markets in the upcoming years are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Merck & Co, Allergan, AstraZeneca, Johnson & Johnson Private Limited, Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Gilead Sciences, Amgen Inc, Eli Lilly, AbbVie Inc, Lupin, Allergan and others.

Learn more about the emerging therapies & key companies @ https://www.delveinsight.com/sample-request/atherosclerosis-market

Atherosclerosis Report Key Insights

1. Atherosclerosis Patient Population

2. Atherosclerosis Market Size and Trends

3. Key Cross Competition in the Atherosclerosis Market

4. Atherosclerosis Market Dynamics (Key Drivers and Barriers)

5. Atherosclerosis Market Opportunities

6. Atherosclerosis Therapeutic Approaches

7. Atherosclerosis Pipeline Analysis

8. Atherosclerosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Atherosclerosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Atherosclerosis Competitive Intelligence Analysis

4. Atherosclerosis Market Overview at a Glance

5. Atherosclerosis Disease Background and Overview

6. Atherosclerosis Patient Journey

7. Atherosclerosis Epidemiology and Patient Population

8. Atherosclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Atherosclerosis Unmet Needs

10. Key Endpoints of Atherosclerosis Treatment

11. Atherosclerosis Marketed Products

12. Atherosclerosis Emerging Therapies

13. Atherosclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Atherosclerosis Market Outlook (7 major markets)

16. Atherosclerosis Access and Reimbursement Overview

17. KOL Views on the Atherosclerosis Market

18. Atherosclerosis Market Drivers

19. Atherosclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Growth in Atherosclerosis Market by 2032: Projections by DelveInsight | Companies- Roche., Teva Pharmaceutical, Sanofi, Pfizer, GlaxoSmithKline, Novartis, Merck, Allergan, AstraZeneca

“Chronic Lymphocytic Leukemia Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Lymphocytic Leukemia pipeline constitutes 55+ key companies continuously working towards developing 60+ Chronic Lymphocytic Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Lymphocytic Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

“Chronic Lymphocytic Leukemia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Lymphocytic Leukemia Market.

Some of the key takeaways from the Chronic Lymphocytic Leukemia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Lymphocytic Leukemia treatment therapies with a considerable amount of success over the years. 
• Chronic Lymphocytic Leukemia companies working in the treatment market are Sana Biotechnology, Novartis, Janssen Research & Development, LLC, NovalGen Ltd, Genmab, Ascentage Pharma Group Inc, Loxo Oncology, and others, are developing therapies for the Chronic Lymphocytic Leukemia treatment 

• Emerging Chronic Lymphocytic Leukemia therapies in the different phases of clinical trials are- SG 299, JBH492, JNJ-64264681, NVG-111, Epcoritamab, APG2575, Pirtobrutinib, and others are expected to have a significant impact on the Chronic Lymphocytic Leukemia market in the coming years.   
• In August 2022, The Food and Drug Administration approved AstraZeneca’s tablet formulation of Calquence, a medication used to treat Small Lymphocytic Leukemia (SLL), Relapsed or Refractory Mantle Cell Lymphoma (MCL), and Chronic Lymphocytic Leukemia (CLL).
• In June 2022, The Phase 2 CAPTIVATE study evaluated IMBRUVICA (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Janssen Pharmaceutical Companies of Johnson & Johnson released new and updated results from this trial.

Chronic Lymphocytic Leukemia Overview

The blood malignancy known as chronic lymphocytic leukemia (CLL) is one kind. It is the most prevalent type of adult leukemia. It occurs when healthy bone marrow lymphocytes (white blood cells) have a mutation that turns them into malignant cells that proliferate and eliminate healthy platelets and blood cells.

Get a Free Sample PDF Report to know more about Chronic Lymphocytic Leukemia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-pipeline-insight

Emerging Chronic Lymphocytic Leukemia Drugs Under Different Phases of Clinical Development Include:

• SG 299: Sana Biotechnology
• JBH492: Novartis Pharmaceuticals
• JNJ-64264681: Janssen Research & Development, LLC
• NVG-111: NovalGen Ltd
• Epcoritamab: Genmab
• APG2575: Ascentage Pharma Group Inc
• Pirtobrutinib: Loxo Oncology

Chronic Lymphocytic Leukemia Route of Administration

Chronic Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Chronic Lymphocytic Leukemia Molecule Type

Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

Chronic Lymphocytic Leukemia Pipeline Therapeutics Assessment

• Chronic Lymphocytic Leukemia Assessment by Product Type
• Chronic Lymphocytic Leukemia By Stage and Product Type
• Chronic Lymphocytic Leukemia Assessment by Route of Administration
• Chronic Lymphocytic Leukemia By Stage and Route of Administration
• Chronic Lymphocytic Leukemia Assessment by Molecule Type
• Chronic Lymphocytic Leukemia by Stage and Molecule Type

DelveInsight’s Chronic Lymphocytic Leukemia Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Lymphocytic Leukemia product details are provided in the report. Download the Chronic Lymphocytic Leukemia pipeline report to learn more about the emerging Chronic Lymphocytic Leukemia therapies

Some of the key companies in the Chronic Lymphocytic Leukemia Therapeutics Market include:

Key companies developing therapies for Chronic Lymphocytic Leukemia are – F. Hoffmann-La Roche Ltd, AstraZeneca, Secura Bio, Inc, Novartis AG, AbbVie, Inc., Gilead Sciences, Inc., BeiGene, Inc., Sanofi (Genzyme Corporation), Ziopharm Oncology Inc, Ono pharmaceuticals Co Ltd, Teva Pharmaceutical Industries, and others.

Chronic Lymphocytic Leukemia Pipeline Analysis:

The Chronic Lymphocytic Leukemia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment.
• Chronic Lymphocytic Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Lymphocytic Leukemia drugs and therapies

Chronic Lymphocytic Leukemia Pipeline Market Drivers

• Rise in Global Prevalence of Chronic Lymphocytic Leukemia Coupled with the Increasing Geriatric Population, huge Product Pipeline along with Growing Research Activities are some of the important factors that are fueling the Chronic Lymphocytic Leukemia Market.

Chronic Lymphocytic Leukemia Pipeline Market Barriers

• However, higher Cost of the Patented Drugs and Therapies, side Effects Associated with Chemotherapy and other factors are creating obstacles in the Chronic Lymphocytic Leukemia Market growth.

Scope of Chronic Lymphocytic Leukemia Pipeline Drug Insight    

• Coverage: Global
• Key Chronic Lymphocytic Leukemia Companies: Sana Biotechnology, Novartis, Janssen Research & Development, LLC, NovalGen Ltd, Genmab, Ascentage Pharma Group Inc, Loxo Oncology, and others
• Key Chronic Lymphocytic Leukemia Therapies: SG 299, JBH492, JNJ-64264681, NVG-111, Epcoritamab, APG2575, Pirtobrutinib, and others
• Chronic Lymphocytic Leukemia Therapeutic Assessment: Chronic Lymphocytic Leukemia current marketed and Chronic Lymphocytic Leukemia emerging therapies
• Chronic Lymphocytic Leukemia Market Dynamics: Chronic Lymphocytic Leukemia market drivers and Chronic Lymphocytic Leukemia market barriers 

Request for Sample PDF Report for Chronic Lymphocytic Leukemia Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Lymphocytic Leukemia Report Introduction

2. Chronic Lymphocytic Leukemia Executive Summary

3. Chronic Lymphocytic Leukemia Overview

4. Chronic Lymphocytic Leukemia- Analytical Perspective In-depth Commercial Assessment

5. Chronic Lymphocytic Leukemia Pipeline Therapeutics

6. Chronic Lymphocytic Leukemia Late Stage Products (Phase II/III)

7. Chronic Lymphocytic Leukemia Mid Stage Products (Phase II)

8. Chronic Lymphocytic Leukemia Early Stage Products (Phase I)

9. Chronic Lymphocytic Leukemia Preclinical Stage Products

10. Chronic Lymphocytic Leukemia Therapeutics Assessment

11. Chronic Lymphocytic Leukemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Lymphocytic Leukemia Key Companies

14. Chronic Lymphocytic Leukemia Key Products

15. Chronic Lymphocytic Leukemia Unmet Needs

16 . Chronic Lymphocytic Leukemia Market Drivers and Barriers

17. Chronic Lymphocytic Leukemia Future Perspectives and Conclusion

18. Chronic Lymphocytic Leukemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring Advancements in Chronic Lymphocytic Leukemia Pipeline, 2023 Updates | Recent FDA, EMA, and PMDA Approvals | Sana Biotechnology, Novartis, Janssen Research, NovalGen, Genmab

“Marginal Zone Lymphoma Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Marginal Zone Lymphoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Marginal Zone Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Marginal Zone Lymphoma Market.

Some of the key takeaways from the Marginal Zone Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Marginal Zone Lymphoma treatment therapies with a considerable amount of success over the years. 
• Marginal Zone Lymphoma companies working in the treatment market are Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others, are developing therapies for the Marginal Zone Lymphoma treatment 

• Emerging Marginal Zone Lymphoma therapies in the different phases of clinical trials are- AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others are expected to have a significant impact on the Marginal Zone Lymphoma market in the coming years.  
• In August 2022, The first patient in a company-sponsored Phase I/II research assessing a conveniently available, cryopreserved formulation of GDA-201 for the treatment of follicular, diffuse large B cell lymphomas, as well as marginal zone lymphoma or mantle cell lymphoma, has been dosed, according to Gamida Cell.
• In August 2022, The China National Medical Products Administration (NMPA) approved Orelabrutinib’s supplemental New Drug Application (sNDA) for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma (R/R MZL).
• In June 2022, In LOTIS-7, a Phase 1b clinical trial assessing ZYNLONTA in conjunction with various anti-cancer medications in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, ADC Therapeutics reported that the first patient has received a dosage. ZYNLONTA in combination with polatuzumab vedotin will be tested for safety and efficacy in the first arm of the LOTIS-7 open-label, multi-center, multi-arm Phase Ib trial. The patients in this trial will be those with relapsed or refractory B-cell non-Hodgkin lymphomas, such as diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma.
• In May 2022, The CIRLL clinical trial (CIRM-0001), a Phase I/II experiment, is being evaluated by Oncternal Therapeutics for zilovertamab in combination with ibrutinib in two different patient groups: one for MCL and the other for CLL. The dose-finding cohorts for MCL and CLL, the dose-expansion cohort for MCL and CLL, and the randomized Phase II cohort for CLL have all reached enrollment completion. Recently, up to ten patients with marginal zone lymphoma (MZL) were included to a dose-expansion group. We anticipate that enrollment will start in Q2 2022. 

Marginal Zone Lymphoma Overview

A subset of indolent (slow-growing) NHL B-cell lymphomas known as marginal zone B-cell lymphoma or marginal zone lymphoma (MZL) make up for 5–17% of all NHL cases.

Get a Free Sample PDF Report to know more about Marginal Zone Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight

Emerging Marginal Zone Lymphoma Drugs Under Different Phases of Clinical Development Include:

• AS-1763: Carna Biosciences
• Amdizalisib (HMPL689): Hutchmed
• Parsaclisib (IBI376): Incyte/Innovent
• Tafasitamab: MorphoSys/Incyte
• Zanubrutinib: Beigene
• Orelabrutinib: InnoCare Pharma
• Tafasitamab: Incyte Corporation
• MIL62: Beijing Mabworks Biotech Co.
• Zandelisib: MEI Pharma, Inc./Kyowa Kirin         
• Loncastuximab: ADC Therapeutics
• LOXO-305: Loxo Oncology
• ADI-001: Adicet Bio
• CDX-1140: Celldex Therapeutics Inc

Marginal Zone Lymphoma Route of Administration

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Marginal Zone Lymphoma Molecule Type

Marginal Zone Lymphoma Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Marginal Zone Lymphoma Pipeline Therapeutics Assessment

• Marginal Zone Lymphoma Assessment by Product Type
• Marginal Zone Lymphoma By Stage and Product Type
• Marginal Zone Lymphoma Assessment by Route of Administration
• Marginal Zone Lymphoma By Stage and Route of Administration
• Marginal Zone Lymphoma Assessment by Molecule Type
• Marginal Zone Lymphoma by Stage and Molecule Type

DelveInsight’s Marginal Zone Lymphoma Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Marginal Zone Lymphoma product details are provided in the report. Download the Marginal Zone Lymphoma pipeline report to learn more about the emerging Marginal Zone Lymphoma therapies

Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:

Key companies developing therapies for Marginal Zone Lymphoma are – Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, and others.

Marginal Zone Lymphoma Pipeline Analysis:

The Marginal Zone Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
• Marginal Zone Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Marginal Zone Lymphoma drugs and therapies

Marginal Zone Lymphoma Pipeline Market Drivers

• Increasing Prevalence, increased research and development are some of the important factors that are fueling the Marginal Zone Lymphoma Market.

Marginal Zone Lymphoma Pipeline Market Barriers

• However, therapies with moderately good patient outcomes, long treatment course and other factors are creating obstacles in the Marginal Zone Lymphoma Market growth.

Scope of Marginal Zone Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Marginal Zone Lymphoma Companies: Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others
• Key Marginal Zone Lymphoma Therapies: AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others
• Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
• Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers 

Request for Sample PDF Report for Marginal Zone Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Marginal Zone Lymphoma Report Introduction

2. Marginal Zone Lymphoma Executive Summary

3. Marginal Zone Lymphoma Overview

4. Marginal Zone Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Marginal Zone Lymphoma Pipeline Therapeutics

6. Marginal Zone Lymphoma Late Stage Products (Phase II/III)

7. Marginal Zone Lymphoma Mid Stage Products (Phase II)

8. Marginal Zone Lymphoma Early Stage Products (Phase I)

9. Marginal Zone Lymphoma Preclinical Stage Products

10. Marginal Zone Lymphoma Therapeutics Assessment

11. Marginal Zone Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Marginal Zone Lymphoma Key Companies

14. Marginal Zone Lymphoma Key Products

15. Marginal Zone Lymphoma Unmet Needs

16 . Marginal Zone Lymphoma Market Drivers and Barriers

17. Marginal Zone Lymphoma Future Perspectives and Conclusion

18. Marginal Zone Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring Marginal Zone Lymphoma Pipeline: Recent FDA, EMA, and PMDA Approvals, Innovative Therapies, Clinical Trials, and Treatment Prospects by Hutchmed, Incyte, Innovent, MorphoSys, Beigene

“Diabetic Retinopathy Market”

(Albany, USA) DelveInsight’s “Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Diabetic Retinopathy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Diabetic Retinopathy market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Diabetic Retinopathy market.

Request for a Free Sample Report @ Diabetic Retinopathy Market Forecast

Some facts of the Diabetic Retinopathy Market Report are:

• According to DelveInsight, Diabetic Retinopathy market size is expected to grow at a decent CAGR by 2032.
• Leading Diabetic Retinopathy companies working in the market are Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences, OcuTerra Therapeutics, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd, LEO Pharma, AstraZeneca, Glenmark Pharmaceuticals, Sanofi, Abbott, Abbvie, Merck, Pfizer, and others.
• Key Diabetic Retinopathy Therapies expected to launch in the market are BAY 1101042, OPT-302, RGX 314, Runcaciguat, OTT166, others.
• The total Diabetic Retinopathy prevalent cases in the 7MM were 12,585,769 in 2021.
• OTT-166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose-engineered to have the required physiochemical characteristics to be able to reach the retina from eye drop application. Phase 1b clinical trials of OTT-166 eye drops have demonstrated safety, tolerability, and clear clinical evidence of biological activity. OcuTerra is currently studying the safety, efficacy, and optimal dosing regimen of OTT166 through the Phase II DR: EAM (Diabetic Retinopathy: Early Active Management) study in patients with moderately-severe to severe non-proliferative and mild proliferative diabetic retinopathy.
• RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDE, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314.

Diabetic Retinopathy Overview

Diabetic retinopathy is a diabetes-related eye disease characterized by damage to the blood vessels in the retina, leading to vision loss and blindness; it is caused by prolonged exposure to high blood sugar levels, resulting in weak, leaky, and blocked vessels, and can progress from non-proliferative retinopathy to proliferative retinopathy with abnormal blood vessel growth; symptoms include blurred vision, color vision impairment, and floaters; diagnosis involves comprehensive eye examinations, retinal examinations, and imaging tests like OCT and fluorescein angiography; treatment options include blood sugar control, laser photocoagulation, intravitreal injections, vitrectomy, and regular eye exams to manage and slow down the disease’s progression.

Learn more about Diabetic Retinopathy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

Diabetic Retinopathy Market

The Diabetic Retinopathy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Retinopathy market trends by analyzing the impact of current Diabetic Retinopathy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Diabetic Retinopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diabetic Retinopathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Diabetic Retinopathy market in 7MM is expected to witness a major change in the study period 2019-2032.

Diabetic Retinopathy Epidemiology

The Diabetic Retinopathy epidemiology section provides insights into the historical and current Diabetic Retinopathy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Diabetic Retinopathy market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Diabetic Retinopathy Epidemiology @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

Diabetic Retinopathy Drugs Uptake

This section focuses on the uptake rate of the potential Diabetic Retinopathy drugs recently launched in the Diabetic Retinopathy market or expected to be launched in 2019-2032. The analysis covers the Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Diabetic Retinopathy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Diabetic Retinopathy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Retinopathy Pipeline Development Activities

The Diabetic Retinopathy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Diabetic Retinopathy key players involved in developing targeted therapeutics.

• KSI-301: Kodiak Sciences
• Brolucizumab: Novartis
• RGX 314: Regenxbio Inc.
• OTT-166: OcuTerra Therapeutics
• OTX-TKI: Ocular Therapeutix
• And others.

Request for a sample report to understand more about the Diabetic Retinopathy pipeline development activities @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

Diabetic Retinopathy Therapeutics Assessment

Major key companies are working proactively in the Diabetic Retinopathy Therapeutics market to develop novel therapies which will drive the Diabetic Retinopathy treatment markets in the upcoming years are Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd, LEO Pharma, AstraZeneca, Glenmark Pharmaceuticals, Sanofi, Abbott, Abbvie, Merck, Pfizer, and others.

Learn more about the emerging Diabetic Retinopathy therapies & key companies @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

Diabetic Retinopathy Report Key Insights

1. Diabetic Retinopathy Patient Population

2. Diabetic Retinopathy Market Size and Trends

3. Key Cross Competition in the Diabetic Retinopathy Market

4. Diabetic Retinopathy Market Dynamics (Key Drivers and Barriers)

5. Diabetic Retinopathy Market Opportunities

6. Diabetic Retinopathy Therapeutic Approaches

7. Diabetic Retinopathy Pipeline Analysis

8. Diabetic Retinopathy Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Diabetic Retinopathy Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Diabetic Retinopathy Competitive Intelligence Analysis

4. Diabetic Retinopathy Market Overview at a Glance

5. Diabetic Retinopathy Disease Background and Overview

6. Diabetic Retinopathy Patient Journey

7. Diabetic Retinopathy Epidemiology and Patient Population

8. Diabetic Retinopathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Retinopathy Unmet Needs

10. Key Endpoints of Diabetic Retinopathy Treatment

11. Diabetic Retinopathy Marketed Products

12. Diabetic Retinopathy Emerging Therapies

13. Diabetic Retinopathy Seven Major Market Analysis

14. Attribute Analysis

15. Diabetic Retinopathy Market Outlook (7 major markets)

16. Diabetic Retinopathy Access and Reimbursement Overview

17. KOL Views on the Diabetic Retinopathy Market

18. Diabetic Retinopathy Market Drivers

19. Diabetic Retinopathy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Growth in Diabetic Retinopathy Market by 2032 as per DelveInsight\’s Estimates | Key Players Include Genentech, Regeneron, Roche, Opthea Limited, Regenxbio, Kodiak Sciences, Ocuphire Pharma

“Migraine Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Migraine pipeline constitutes 30+ key companies continuously working towards developing 30+ Migraine treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Migraine Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.

Some of the key takeaways from the Migraine Pipeline Report:

• Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years. 
• Migraine companies working in the treatment market are Pulmatrix, Vaxxinity, Inc, Tonix Pharmaceuticals, Inc., AEON Biopharma, Inc, Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment 

• Emerging Migraine therapies in the different phases of clinical trials are- PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.   
• In August 2022, An open-label, multiple-dose evaluation of the efficacy and safety of AXS-07 (meloxicam and rizatriptan) for the acute treatment of migraine in adults with a prior inadequate response to an oral CGRP inhibitor was started by Axsome Therapeutics, Inc.
• In May 2022, The U.S. Food and Drug Administration (FDA) has sent Axsome Therapeutics, Inc. a Complete Response Letter (CRL) concerning its New Drug Application (NDA) for AXS-07, which is intended to treat migraines acutely.
• In February 2022, The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved the calcitonin gene-related peptide (CGRP) receptor antagonist Rimegepant, according to a statement from Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. For both the acute treatment of adult episodic migraine (occurring in four or more migraine attacks per month) and the preventive treatment of adult acute migraine with or without aura, the 75 mg dose of rimegepant (available as an oral dissolving tablet) is recommended for marketing authorization.
• In January 2022, A novel fast-acting liquid medication called Elyxyb (celecoxib oral solution) was introduced by BioDelivery Sciences. It’s among the first adult ready-to-use oral migraine treatments that have been approved by the Food and Drug Administration for the acute treatment of migraines, aura or not.

Migraine Overview

Strong headaches are a common side effect of the neurological condition migraine. The headache occurs in spurts and occasionally coexists with light sensitivity, nausea, and vomiting. One of the main causes of impairment in the globe is migraine. About 15% of Americans suffer from migraines.

Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/migraine-pipeline-insight

Emerging Migraine Drugs Under Different Phases of Clinical Development Include:

• PUR-3100: Pulmatrix
• UB-313: Vaxxinity, Inc
• TNX-1900: Tonix Pharmaceuticals, Inc.
• ABP-450: AEON Biopharma, Inc
• LY3451838: Eli Lilly and Company
• STS-101: Satsuma Pharmaceuticals
• AXS 07: Axsome Therapeutics
• Zavegepant: Pfizer

Migraine Route of Administration

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Migraine Molecule Type

Migraine Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule 

Migraine Pipeline Therapeutics Assessment

• Migraine Assessment by Product Type
• Migraine By Stage and Product Type
• Migraine Assessment by Route of Administration
• Migraine By Stage and Route of Administration
• Migraine Assessment by Molecule Type
• Migraine by Stage and Molecule Type

DelveInsight’s Migraine Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies

Some of the key companies in the Migraine Therapeutics Market include:

Key companies developing therapies for Migraine are – Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.

Migraine Pipeline Analysis:

The Migraine pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
• Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Migraine drugs and therapies

Migraine Pipeline Market Drivers

• Increasing prevalence of Migraine, significant progress is being made in the preventative treatment of chronic migraine, growing awareness regarding migraine are some of the important factors that are fueling the Migraine Market.

Migraine Pipeline Market Barriers

• However, lack of proper diagnosis, various side-effects associated with the available drugs and other factors are creating obstacles in the Migraine Market growth.

Scope of Migraine Pipeline Drug Insight    

• Coverage: Global
• Key Migraine Companies: Pulmatrix, Vaxxinity, Inc, Tonix Pharmaceuticals, Inc., AEON Biopharma, Inc, Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, Pfizer, and others
• Key Migraine Therapies: PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, Zavegepant, and others
• Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
• Migraine Market Dynamics: Migraine market drivers and Migraine market barriers 

Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials

Table of Contents

1. Migraine Report Introduction

2. Migraine Executive Summary

3. Migraine Overview

4. Migraine- Analytical Perspective In-depth Commercial Assessment

5. Migraine Pipeline Therapeutics

6. Migraine Late Stage Products (Phase II/III)

7. Migraine Mid Stage Products (Phase II)

8. Migraine Early Stage Products (Phase I)

9. Migraine Preclinical Stage Products

10. Migraine Therapeutics Assessment

11. Migraine Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Migraine Key Companies

14. Migraine Key Products

15. Migraine Unmet Needs

16 . Migraine Market Drivers and Barriers

17. Migraine Future Perspectives and Conclusion

18. Migraine Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Assessment of Migraine Pipeline and Clinical Trials in 2023: FDA Approvals, Therapies, and Companies by DelveInsight | Pulmatrix, Vaxxinity, Inc, Tonix Pharma, AEON Biopharma, Inc, Eli lilly